Clinical observation of leflunomide in the treatment of diabetic nephropathy-IV

• DOI: 10.3760/cma.j.issn.1008-6315.2013.11.027
• Publication Date: 2013-11-01
• Authors: wei Wei; Huimin Wang
• Keywords: Leflunomide

Objective To investigate the curative effect of leflunomide in treatment diabetic nephropathy-Ⅳ (DN-Ⅳ).Methods Sixty cases with DN-Ⅳ were assigned to group and control group.Both groups given hypoglycemic,antihypertensive,regulate lipid angiotensin converting enzyme inhibitors or Ⅱ inhibitor class drugs.Meanwhile patients orally administered once daily for two month a dose 50 mg/d first three days 20 afterwards.24 hour pre-and post-treatment values urinary protein,C-reactive protein (CRP),endogenous creatinine clearance rate (Ccr),triglyceride (TG),total cholesterol (TC),albumin (ALB),glycosylated hemoglobin (HbA1c) blood pressure measured.Analyzed correlation Ccr other laboratory indicators after one year.Results At 24 before treatment,after months year,the level h (n =26) (3.75 ± 0.94)g/24 h,(2.02 0.45) g/24 h,and (2.46 0.55) respectively,and (69.04 13.35) ml/min,(71.35 11.25) ml/min,and (67.48 10.58) ml/min respectively.While group(n =28),the (3.68 1.03) h,(3.43 0.65) (5.46 ±0.47) respectively at time points,and (68.55 10.09) ml/min,(66.76 9.45) ml/min,(57.50 15.75) respectively.The levels year significantly lower than as well corresponding period (P ＜ 0.05),while was higher that same period,and difference statistically significant(P 0.05).The CRP,TG,TC,HbAlc systolic period,while ALB urine protein,TC,systolic correlated (β =-0.771,-0.682,0.656,-0.530respectively;P ＜0.01).Conclusion Leflunomide nephropathy safe effective,but duration second selection therapy needed further study.

Key words: Diabetic nephropathy; Leflunomide; Endogenous